http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101748937-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2814 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5058 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2015-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101748937-B1 |
| titleOfInvention | Methods of screening anti-epileptic or cognitive impairment drugs using Kv4.1 channel |
| abstract | The present invention relates to a method for treating a seizure or cognitive disorder therapeutic candidate substance by treating a neuronal cell expressing potassium channel Kv4.1; Measuring the activity or expression level of potassium channel Kv4.1 in neurons treated with seizure or cognitive disorder therapeutic agent candidate; And the activity or expression level of potassium channel Kv4.1 measured in the above step is higher than that of the control neuron not treated with seizure or cognitive impairment candidate, the seizure or cognitive disorder candidate is administered as a therapeutic agent for seizure or cognitive disorder A method for screening for a seizure or cognitive disorder therapeutic agent comprising the step of determining the activity of potassium channel Kv4.1 and a means for measuring the activity of potassium channel Kv4.1 in neurons expressing potassium channel Kv4.1, . The present invention also relates to a method for assaying the efficacy of a therapeutic agent for seizure or cognitive disorder by measuring the activity or expression level of potassium channel Kv4.1 in neurons expressing potassium channel Kv4.1, Lt; RTI ID = 0.0 > Kv4.1 < / RTI > in a cell. The potassium channel Kv4.1 of the present invention can be screened for a novel seizure or cognitive disorder therapeutic agent by measuring activity and expression independently of seizure or cognitive disorder symptoms independently of other Kv4 channels, It is possible to easily and effectively test the efficacy of a conventional seizure or cognitive disorder treatment agent. |
| priorityDate | 2015-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 209.